AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24916694
Drug: Low-dose Fulvestrant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Fulvestrant
Trial: 20397858
Drug: Hold-Relax-Antagonist Contraction
RxNorm normalized name: dextromethorphan hydrobromide Oral Lozenge [Hold DM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hold-Relax-Antagonist Contraction (HR-AC) stretching technique
Trial: 18498909
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with olmesartan medoxomil (OM) and amlodipine besylate (AML)
Trial: 18498909
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with OM and AML
Trial: 18498909
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil (OM) monotherapy
Trial: 18498909
Drug: Amlodipine besylate
RxNorm normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine besylate (AML) monotherapy
Trial: 18498909
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with OM/AML 20/10 mg and 40/10 mg
Trial: 12526069
Drug: Erythromycin 50
RxNorm normalized name: erythromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 50 mg/kg/day for 14 days
Trial: 12526069
Drug: Amoxicillin 75
RxNorm normalized name: amoxicillin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 75 mg/kg/day for 7 days
Trial: 10536434
Drug: Terbinafine 1%
RxNorm normalized name: Terbinafine 1% Topical application Gel/Jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 1% topical solution for 1 week
Trial: 10536434
Drug: Clotrimazole 1%
RxNorm normalized name: CLOTRIMAZOLE 1% LOTION
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clotrimazole 1% topical solution for 4 weeks
Trial: 10536434
Drug: Terbinafine 1%
RxNorm normalized name: Terbinafine 1% Topical application Gel/Jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 1% solution (subgroup without protocol violation)
Trial: 10536434
Drug: Clotrimazole 1%
RxNorm normalized name: CLOTRIMAZOLE 1% LOTION
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clotrimazole 1% solution (subgroup without protocol violation)
Trial: 8871416
Drug: Behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior therapy plus the nicotine patch (BTP)
Trial: 8871416
Drug: Behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior therapy alone (BT)
Trial: 1649867
Drug: Oral potassium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral potassium supplements
Trial: 6366132
Drug: Simultaneous therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous therapy (MTX 200 mg/m2 IV and 5-FU 600 mg/m2 IV)
Trial: 6366132
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (MTX 200 mg/m2 IV followed by 5-FU 600 mg/m2 IV after one hour)
Trial: 6366132
Drug: Simultaneous therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous therapy (MTX 200 mg/m2 IV and 5-FU 600 mg/m2 IV) among stage III patients
Trial: 6366132
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (MTX 200 mg/m2 IV followed by 5-FU 600 mg/m2 IV after one hour) among stage III patients
Trial: 31529590
Drug: JNJ-9375 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-9375 (0.3 to 1.8 mg/kg)
Trial: 29768313
Drug: Prasugrel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (60 mg orally)
Trial: 29768313
Drug: Clopidogrel (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (600 mg orally)
Trial: 26950829
Drug: Vildagliptin 50
RxNorm normalized name: vildagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 50 mg twice daily (BID)
Trial: 26950829
Drug: Saxagliptin 5
RxNorm normalized name: sAXagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 5 mg once daily (QD)
Trial: 21702254
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg midazolam as pre‐medication 1 hour preoperatively
Trial: 21702254
Drug: Placebo as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as pre‐medication
Trial: 17339813
Drug: Medication intervention,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication intervention, frequency 3 to 5 times per week, duration 45 to 60 minutes, total period 12 to 24 weeks.
Trial: 16382062
Drug: Repeated thrombolysis
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated thrombolysis vs Conservative therapy
Trial: 16382062
Drug: Rescue PCI
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue PCI vs Conservative therapy
Trial: 9856539
Drug: Drinking milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinking milk (300 ml)
Trial: 9856539
Drug: Drinking water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinking water (300 ml)
Trial: 7796718
Drug: Current users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current users of anabolic steroids
Trial: 7796718
Drug: Former users
RxNorm normalized name: Triple Wormer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Former users of anabolic steroids
Trial: 7796718
Drug: Non-users of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-users of anabolic steroids
Trial: 2131953
Drug: Alginate-antacid (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginate-antacid (1 tablet to be chewed 30 min after each meal and at bed time)
Trial: 2131953
Drug: Famotidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (1 mg/kg before supper at 7 pm)
Trial: 374847
Drug: Commercial aqueous
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial aqueous pilocarpin solution
Trial: 30614850
Drug: Hyoscine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine 0.3 mg
Trial: 27557443
Drug: Biofeedback treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback treatment (8-11 sessions of Electromyography biofeedback, Vasoconstriction-/Vasodilatation training, or a combination)
Trial: 22224655
Drug: Curcumin (L-D+)
DrugBank: Curcumin sulfate (DB14635)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (L-D+)
Trial: 22224655
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (L+D+)
Trial: 17706718
Drug: Detrusor injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detrusor injection of 100 U botulinum toxin type A
Trial: 17706718
Drug: Suburothelial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suburothelial injection of 100 U botulinum toxin type A
Trial: 17706718
Drug: Bladder base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bladder base injection of 100 U botulinum toxin type A
Trial: 2724028
Drug: 0.05% NaF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% NaF solution (control)
Trial: 29124991
Drug: Oral appliance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral appliance treatment
Trial: 27114587
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate during interim maintenance 1
Trial: 27114587
Drug: Dexamethasone and
RxNorm normalized name: dexamethasone and antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone and high-dose methotrexate
Trial: 23535292
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg bid BDP + RTV for 28 days
Trial: 23535292
Drug: 600/100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600/100 mg bid BDP + DRV/r for 28 days
Trial: 19853533
Drug: EBRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBRT with rV(100%) >= 0.05 cc
Trial: 19853533
Drug: EBRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBRT with rV(100%) < 0.05 cc
Trial: 19853533
Drug: EBRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBRT with dose to hottest 0.1 cc
Trial: 19853533
Drug: EBRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBRT with dose to hottest 1%
Trial: 19853533
Drug: EBRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBRT with dose to hottest 3%
Trial: 18212693
Drug: Group corticosteroid
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group corticosteroid (Group S) received 6-methylprednisolone 15 mg/kg IV 60 min before induction.
Trial: 18212693
Drug: Group TEA+corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group TEA+corticosteroid (Group TEA+S) received 20 mg bupivacaine in bolus 60 min before induction followed by 20 mg/h bupivacaine infusion intraoperatively and postoperatively via epidural catheter.
Trial: 18212693
Drug: Group TEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group TEA (Group TEA) received 20 mg bupivacaine in bolus 60 min before induction followed by 20 mg/h bupivacaine infusion intraoperatively and postoperatively via epidural catheter.
Trial: 18212693
Drug: Group control
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group control (Group C) received neither preinduction TEA nor a preinduction steroid.
Trial: 9128319
Drug: MISO TID
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MISO TID (200 microg three times daily)
Trial: 9128319
Drug: MISO BID
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MISO BID (200 microg two times daily)
Trial: 9128319
Drug: RAN (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAN (150 mg twice daily)
Trial: 28131706
Drug: Device-managed automatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Device-managed automatic therapy for atrial tachycardia or fibrillation (AT/AF)
Trial: 28131706
Drug: In-hospital approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-hospital approach for treatment of symptomatic AT/AF
Trial: 26780278
Drug: 1000 IU
RxNorm normalized name: D 1000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 IU vitamin D3 plus 500 mg calcium
Trial: 23278367
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of tenofovir dipivoxil fumarate 150 mg
Trial: 23278367
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of tenofovir dipivoxil fumarate 300 mg
Trial: 23278367
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of tenofovir dipivoxil fumarate 600 mg
Trial: 23278367
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of tenofovir dipivoxil fumarate 300 mg
Trial: 23278367
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of tenofovir dipivoxil fumarate 300 mg with high-fat meal
Trial: 23278367
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of tenofovir dipivoxil fumarate 300 mg fasting vs multiple doses
Trial: 23278367
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of tenofovir dipivoxil fumarate 300 mg with food
Trial: 10832669
Drug: Ribavirin (Rb)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin (Rb) 1200 mg/day
Trial: 24977293
Drug: Sublingual ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual ketamine wafer (25 mg)
Trial: 24977293
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (10 mg)
Trial: 22731800
Drug: Midazolam and
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam and 25 mg of meperidine
Trial: 22731800
Drug: Midazolam and
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam and 20 mg of hyoscine N‐butylbromide
Trial: 16513605
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) after 4 months
Trial: 16513605
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) after 13 months
Trial: 11737007
Drug: OPFA 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPFA 6 g a day for 16 weeks
Trial: 9148018
Drug: Vaccine +
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine + Immunoglobulin (4 ml given simultaneously with the first vaccine injection)
Trial: 3118589
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg acemetacin t.i.d. for 1 week
Trial: 28522745
Drug: DEG compared
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEG compared to SEG for use of non‐medication aids
Trial: 25315663
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (n=91)
Trial: 23745991
Drug: Curcumin (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (2.0 grams orally three times per day, 6.0 grams daily)
Trial: 9550777
Drug: Adjusted full
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted full intensity oral anticoagulation (target range: 3.0-4.0 INR)
Trial: 9550777
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of low dose aspirin and adjusted low intensity oral anticoagulation (target range: 2.0-2.5 INR)
Trial: 21500879
Drug: Palmtop computer-delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palmtop computer-delivered treatment (CDT) for smoking relapse prevention for one additional month
Trial: 21500879
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further computer-delivered treatment or assessment (EMA-Only)
Trial: 14691684
Drug: Active absorbable
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active absorbable algal calcium (AAA Ca) 900 mg/day
Trial: 11240873
Drug: Intravenous pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pethidine (control group)
Trial: 8318243
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine 0.3 micrograms/kg/hr and fentanyl 25 micrograms/kg
Trial: 30518511
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg) daily until the morning of colonoscopy
Trial: 30518511
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily until the morning of colonoscopy
Trial: 19433391
Drug: Nonpegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpegylated liposomal doxorubicin (NLD) 60 mg/m2 every 3 weeks and trastuzumab loading dose 4 mg/kg followed by 2 mg/kg weekly
Trial: 17024639
Drug: Hemopure (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemopure (30 g)
Trial: 17024639
Drug: Hemopure (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemopure (45 g)
Trial: 11393099
Drug: Multidisciplinary rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary rehabilitation program (MRP) including physical therapy, nurse-supervised exercise, and discharge planning
Trial: 4948417
Drug: Oral streptomycin-dependent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral streptomycin-dependent mutant Shigella vaccines
Trial: 31124836
Drug: Alfaxalone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone (0.5 mg/kg bolus intravenous injection)
Trial: 28814323
Drug: Sarolaner (Simparic™)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarolaner (Simparic™) at 2 mg/kg
Trial: 25665908
Drug: Bone-borne rapid
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone-borne rapid maxillary expansion (miniscrew-implant-based)
Trial: 21348211
Drug: 1 IU
RxNorm normalized name: factor VIII 1 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 IU of oxytocin followed by an infusion of 2.5 IU x h(‐1)
Trial: 21348211
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 20 IU at a rate of 700 mlU x min(‐1) followed by 10 IU x min(‐1)
Trial: 19485969
Drug: Gabapentin (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (900 mg tapering to 600 mg or 1200 mg tapering to 800 mg)
Trial: 19485969
Drug: Lorazepam (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (6 mg tapering to 4 mg)
Trial: 12760978
Drug: Dexamethasone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (4 mg x2)
Trial: 11129502
Drug: Chlorambucil therapy
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorambucil therapy starting with 0.8 mg/kg/4 days, increased by 0.1 mg/kg/4 days cycle
Trial: 11129502
Drug: Chlorambucil therapy
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorambucil therapy
Trial: 2578971
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of half doses of terbutaline (5 mg twice daily) and theophylline (250 mg twice daily)
Trial: 2578971
Drug: Theophylline alone
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline alone (500 mg twice daily)
Trial: 2578971
Drug: High-dose combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose combination treatment (theophylline 500 mg twice daily and terbutaline 10 mg twice daily)
Trial: 2578971
Drug: High-dose combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose combination treatment
Trial: 26196199
Drug: Oral nutrition
RxNorm normalized name: BAGS/TUBES/SUPPLIES FOR ORAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutrition (PO) with medium-chain triglyceride (MCT) formula
Trial: 27886064
Drug: Probiotic supplement
RxNorm normalized name: Align Probiotic Supplement Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplement (1 × 10^10 CFU of multi-species probiotics)
Trial: 24452372
Drug: Single-session 90-min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-session 90-min Acceptance-Based Behavioral Therapy (ABBT) workshop
Trial: 22428464
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg aspirin (high HDL group)
Trial: 18490496
Drug: Amlodipine besylate
RxNorm normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine besylate and olmesartan medoxomil (fixed-dose combination)
Trial: 18490496
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with amlodipine or olmesartan
Trial: 16174115
Drug: Aortic dissection
RxNorm normalized name: chloroxylenol / hydrocortisone / pramoxine hydrochloride Otic Solution [Cortic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aortic dissection (AD) surgical treatment
Trial: 16174115
Drug: Aortic dissection
RxNorm normalized name: chloroxylenol / hydrocortisone / pramoxine hydrochloride Otic Solution [Cortic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aortic dissection (AD) medical treatment
Trial: 11040176
Drug: 6-mercaptopurine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-mercaptopurine (1.5 mg x kg(‐1) x day(‐1)) + prednisone (40 mg/day)
Trial: 11040176
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + prednisone (40 mg/day)